An Australian stem cell and regenerative medicine company

FAQ: Cynata Partner apceth GmbH & Co Completes Cymerus™ Evaluation

Cynata’s technology was investigated by German Company apceth GmbH & Co. KG, what did this result in?

Cynata’s Cymerus™ mesenchymal stem cell (MSC) technology was assessed in apceth’s in-house cell culture and genetic modification systems. The outcome was considered by both parties to be very successful. The activity was undertaken as part of the option agreement between the two parties and was designed to evaluate the applicability of Cynata’s MSCs in apceth’s unique approach to engineering new properties into MSCs, not only for use in treating cancer but also in treating a number of other devastating diseases. apceth’s evaluation demonstrated not only the success of the Cymerus™ platform but its ability to successfully integrate with other technologies.

Subsequent to apceth completing the successful evaluation of Cynata’s Cymerus™ technology the company reviewed its internal strategy and decided to focus on its contract manufacturing business. However the promising results open the field of oncology (and more broadly) for Cynata to engage in discussions with other biopharmaceutical companies around genetically engineered MSCs.

Will Cynata continue research in cancer?

Cynata has completed a successful research program in genetically modified MSCs in cancer through a collaboration with Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School. The apceth evaluation was very helpful in providing additional confirmatory data that Cynata’s Cymerus technology is very appropriate for use in genetic modification to enhance cancer-killing properties of the cells. Find out more here: https://www.bioinformant.com/cynata-therapeutics-and-harvard-to-target-cancer-with-toxin-secreting-stem-cells/cancer-treatment/

What else is Cynata working on?

Cynata has proved that the Cymerus technology is effective in various animal models of specific diseases. In a world-first, Cynata has completed a clinical trial of CYP-001, a patented Cymerus product for graft-versus-host disease (GvHD), meeting all safety and efficacy endpoints. This provides a sound foundation for fast tracking development and commercialization of the platform technology for further diseases that represent major unmet medical needs, including in asthma, organ transplantation, diabetic wounds, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.  Further details of Cynata's clinical pipeline may be found elsewhere on the website.